Welcome to our dedicated page for NEXGEL SEC filings (Ticker: NXGLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NEXGEL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NEXGEL's regulatory disclosures and financial reporting.
NexGel, Inc. filed a current report to disclose that it is using a new investor presentation as of June 17, 2026. The presentation is provided as Exhibit 99.1 and is being furnished under Regulation FD, meaning it is for information purposes and not treated as filed financial reporting.
The company states that this investor presentation will not be incorporated into other securities law filings unless specifically referenced. No new financial results, major transactions, or operational changes are described in this report itself.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported an open-market sale of common stock. On June 11, 2026, he sold 3,000 shares at $0.6136 per share. After this transaction, he continues to directly hold 333,692 shares of NEXGEL common stock.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported open-market sales of company common stock. He sold 3,000 shares at $0.5936 per share on June 4 and 3,000 shares at $0.5470 per share on June 8. After these transactions, he directly holds 336,692 shares of NEXGEL common stock, indicating he retained the vast majority of his position.
NexGel, Inc. is asking stockholders at its July 10, 2026 annual meeting to approve seven proposals, including a large potential share issuance tied to recent convertible note and warrant financings, a move from Delaware to Nevada, and significant changes to its capital structure.
Proposal 2 seeks approval under Nasdaq rules to issue more than 19.99% of currently outstanding common stock upon conversion of unsecured convertible notes and exercise of related warrants, which could result in substantial dilution if fully converted. Proposals 3–5 would reincorporate NexGel in Nevada and, either through the new Nevada charter or as Delaware fallbacks, increase authorized common stock from 25,000,000 to 100,000,000 and permit a discretionary 1‑for‑2 to 1‑for‑10 reverse stock split. As of the June 3, 2026 record date, 9,225,242 common shares were outstanding. Stockholders are also asked to elect seven directors, approve executive pay on an advisory basis, and ratify the 2026 auditor.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported selling a total of 13,000 shares of Common Stock in open-market transactions over three days. He sold 3,000 shares at $0.5975 per share, 7,000 shares at a weighted average price of $0.6058 per share, and 3,000 shares at $0.6003 per share. Following these sales, he directly holds 344,692 shares of NEXGEL Common Stock, indicating these sales represent a relatively small portion of his overall position.
NEXGEL director Henry Scott Robert acquired new derivative securities linked to the company’s common stock. He received a Convertible Promissory Note with an original principal amount of $25,000, which is convertible into up to 41,667 shares of common stock at an initial conversion price of $0.60 per share.
He also received a Warrant to Purchase Common Stock for 20,834 shares at an initial exercise price of $0.80 per share. Both the note and warrant are exercisable at his option, subject to a 4.99% beneficial-ownership limitation and other specified conditions.
NEXGEL director Brian Joseph Kieser bought a $1,000,000 Convertible Promissory Note and received a large stock warrant as part of the same financing. The Note can be converted into up to 1,666,667 shares of common stock at $0.60 per share. The warrant is exercisable for 833,334 shares at $0.80 per share. Both instruments are convertible or exercisable at the holder’s option but are subject to a 4.99% beneficial-ownership limitation on NEXGEL’s outstanding common stock.
NEXGEL, INC. reported that Chief Executive Officer Adam R. Levy acquired derivative securities linked to its common stock. He received a Convertible Promissory Note with an original principal amount of $60,000, which is convertible into up to 100,000 shares of common stock at $0.60 per share. He also received a Warrant to Purchase Common Stock for 50,000 shares at an initial exercise price of $0.80 per share, issued as part of the consideration for purchasing the note. Both the note and warrant are exercisable at any time at his option, subject to a 4.99% beneficial-ownership limitation that restricts conversion or exercise if it would push ownership above that threshold.
NEXGEL, INC. director Brian Joseph Kieser has filed an initial ownership report showing indirect derivative positions held through Sequence LifeScience, Inc. The holdings include a warrant to acquire 4,583,334 shares of common stock at an exercise price of 0.8000, expiring on 2031-04-17, and a convertible promissory note convertible into 9,166,667 shares at 0.6000, expiring on 2027-10-17. Both instruments are exercisable or convertible at the holder’s option but are subject to a 4.99% beneficial-ownership limitation and other terms. Kieser is the indirect sole owner of Sequence and may be deemed to share voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.